Navigation Links
New England Journal of Medicine Publishes New Data on Gardasil,,Merck's Cervical Cancer Vaccine

, 990.8) for anti-HPV 11, 3056.9 (95% CI: 2594.4, 3601.8) for anti-HPV 16, and 527.2 (95% CI: 450.9, 616.5) for anti-HPV 18. The GMTs for women who did not nurse during vaccine administration were 540.1 (95% CI: 523.5, 557.2) for anti-HPV 6, 746.3 (95% CI: 720.4, 773.3) for anti-HPV 11, 2290.8 (95% CI: 2180.7, 2406.3) for anti-HPV 16, and 456.0 (95% CI: 438.4, 474.3) for anti-HPV 18. Overall, 17 and 9 infants of subjects who received GARDASIL or placebo, respectively (representing 3.4% and 1.8% of the total number of subjects who were breast-feeding during the period in which they received GARDASIL or placebo, respectively), experienced a serious adverse experience. None was judged by the investigator to be vaccine related. In clinical studies, a higher number of breast-feeding infants (n = 6) whose mothers received GARDASIL had acute respiratory illnesses within 30 days post-vaccination of the mother as compared to infants (n = 2) whose mothers received placebo. In these studies, the rates of other adverse experiences in the mother and the nursing infant were comparable between vaccination groups. Pediatric Use The safety and efficacy of GARDASIL have not been evaluated in children younger than 9 years. Geriatric Use The safety and efficacy of GARDASIL have not been evaluated in adults above the age of 26 years. ADVERSE REACTIONS In 5 clinical trials (4 placebo-controlled), subjects were administered GARDASIL or placebo on the day of enrollment, and approximately 2 and 6 months thereafter. Few subjects (0.1%) discontinued due to adverse experiences. In all except 1 of the clinical trials, safety was evaluated using vaccination report card (VRC)-aided surveillance for 14 days after each injection of GARDASIL or placebo. The subjects who were monitored using VRC-aided surveillance included 5088 girls and women 9 through 26 years of age at enrollment who received GARDASIL and 3790 girls and women who receive
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
2. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... AMRI (NASDAQ: AMRI ), a leading ... appointment of Ian Shott as President of AMRI Europe, ... In this newly created role, Mr. Shott will have ... company,s site in Wales, United Kingdom, and work closely ...
... SALT LAKE CITY, May 22, 2012   USANA Health ... global nutritional supplement company, today announced the promotion of ... and development and Dr. Brian Dixon to executive director ... Steely, a licensed naturopathic physician, Mark Levy, a Ph.D. ...
Cached Medicine Technology:AMRI Announces President for AMRI Europe 2AMRI Announces President for AMRI Europe 3USANA Health Sciences Expands Award-Winning Research and Development Team 2USANA Health Sciences Expands Award-Winning Research and Development Team 3
(Date:12/26/2014)... 2014 DW-InductionHeating.com (DaWei Induction Heating Co.) ... and developing, producing and marketing of a series of ... announces their new series of induction brazing equipments ... company, induction brazing refers to the joining ... material and heat. The manager says that there are ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... it has received approval from the U.S. Food and ... gum USP, 2 mg (coated fruit) and 4 mg ... marketed under store brand labels and is comparable to ... aid to smoking cessation. "This first store brand approval ...
... the advent of a possible new blockbuster drug and ... and drug addictions, global sales of smoking cessation and ... of little over $1.1 billion in 2005 to more ... and Addiction Treatments: A World Market Analysis, a new ...
... of mobile phones in the provision of clinical care are ... and Safety in Health Care argues. ,Healthcare ... to help improve the provision of care to people with ... disease. ,The UK and the US are leading ...
... Medarex, Inc. today announced a collaborative research agreement ... Chemical Holdings Corporation . The two companies expect ... against a Mitsubishi target for the potential treatment ... Medarex's UltiMAb Human Antibody Development System(R) to generate ...
... the most common addiction all over the world, and a ... impact of tobacco in its various forms on human health, ... smoking. ,Tobacco generates about Rs.7,964 crore ... about Rs.27,661 crore, according to WHO estimates. ...
... risk the wrath of the country's 350 million smokers today by ... ,"It will be applied in all Olympic venues and ... ,A sign of the passions the issue can raise ... ,Earlier this month, an attempt by security guards ...
Cached Medicine News:Health News:Perrigo Receives FDA Approval to Market Coated Fruit Nicotine Gum 2Health News:Urgent Need for Guidance on Mobile Phone Use in Clinical Care 2Health News:Tobacco Menace and What can Be Done About It 2Health News:Tobacco Menace and What can Be Done About It 3Health News:Tobacco Menace and What can Be Done About It 4Health News:China Bans Smoking at Olympics 2